← Therapy pipeline
Investigational · Obesity development

Elecoglipron

AZD5004 · ECC5004 · AstraZeneca / Eccogene

Once-daily oral small-molecule GLP-1 agonist.

GLP-1
Other study areas
Type 2 diabetesCardiovascular outcomesKidney outcomesHeart failureKidney disease
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 3Updated as of November 2026
SponsorAstraZeneca / Eccogene
TargetsGLP-1
RouteOral tablet
DevelopmentObesity-specific
01 / Evidence

Selected study results

VISTA · 36-week follow-upMean weight changeBody weight decreased 11.8% · 36 weeks · Phase 2b
Phase 2b · Oral · Sponsor-reported numerical results

Mean weight change · 36 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
11.8%
Placebo / comparator
0.3%

Adults with obesity or overweight plus a weight-related complication · 75 mg daily, dose escalation every two weeks, vs placebo · Trial N=310 · Efficacy estimand. Results & methods ↗

Additional results or analyses from this same study
  • Primary timepoint · 26 weeksMean weight change was −10.5% versus −0.6% with placebo at 26 weeks. The 36-week values above are later follow-up in the same study.

Efficacy estimand; this is follow-up of the same VISTA trial, not a separate study.

SOLSTICE · type 2 diabetesMean HbA1c changeHbA1c decreased 1.9 percentage points · 26 weeks · Phase 2b
Phase 2b · Oral · Published trial; numbers from sponsor report

Mean HbA1c change · 26 weeks

Study focus: Glycemic control in type 2 diabetes

Elecoglipron 75 mg
1.9 percentage points
Placebo
0.2 percentage points

Adults with type 2 diabetes · 75 mg daily, dose escalation every two weeks, vs placebo · Trial N=404 · Efficacy estimand. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Body-weight endpoint · same studyMean weight change was −7.7% versus −1.7% with placebo at 26 weeks; the primary endpoint was HbA1c.

An open-label oral semaglutide arm was exploratory; this card shows the placebo comparison.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Oral tabletOnce daily
Phase 3Initiated
Milestone → next

Latest: Positive Phase 2b VISTA and SOLSTICE results; Phase 3 includes the obesity EMBOLD program and type 2 diabetes ELUMINATE studies.

Next: EMBOLD weight-management and ELUMINATE diabetes results; cardiovascular and kidney outcomes are also under development.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 3 studies1 record

Phase 3

EMBOLD

Weight management
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Registered master protocol for adults with obesity or overweight, with and without type 2 diabetes. Individual study populations are specified in the registry.

Phase 2 studies1 record

Phase 2b

VISTA

Weight management
Study: CompletedResults: Sponsor results shown aboveStatus reviewed November 2026

Adults with obesity or overweight and at least one weight-related comorbidity; oral dose-ranging weight-management study.

Related conditions and outcomes

Phase 3 studies3 records

Phase 3

Elecoglipron · chronic kidney disease

Kidney outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Separate Phase 3 related-condition study; registry recruiting. Kidney outcomes are distinct from obesity efficacy.

Phase 3

Elecoglipron · heart failure

Heart-failure outcomes
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Separate Phase 3 related-condition study; registry recruiting. Heart-failure outcomes are distinct from obesity efficacy.

Phase 2 studies1 record

Phase 2b

SOLSTICE

Glycemic control in type 2 diabetes
Study: CompletedResults: Published paper; sponsor figures shown aboveStatus reviewed November 2026

Adults with type 2 diabetes; glycemic-control study with placebo and an exploratory semaglutide comparator.